Merck & Co. Inc.'s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck (MRK) said a trial of the drug, given ...

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its ...

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...

Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...

Subcutaneous pembrolizumab matched IV Keytruda in key pharmacokinetic metrics in a Phase 3 NSCLC trial. Safety and efficacy ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...

in patients with metastatic non-small cell lung cancer (NSCLC). The randomized, open-label phase 3 MK-3475A-D77 trial (ClinicalTrials.gov Identifier: NCT05722015) evaluated the pharmacokinetics (PK) ...

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...